In an additional analysis of the primary endpoint pre-specified in the protocol, the percentage of patients who achieved and maintained complete episode remission during the last 14 days of the study was 76 percent in the Zenvia 30/10 mg group, 80 percent in the 20/10 mg group and 61 percent in the placebo group
Data indicated that, at day 42, the 14-day dose resulted in 53.7 percent complete clearance vs. 4.5 percent in the placebo arm, while the 28-day dose resulted in 45.7 percent complete clearance rate vs. 10 percent in the placebo group
In the BRAVO study, in branch-RVO, patients who received 0.3 mg of Lucentis had a mean gain from baseline BCVA of 16.6 letters, while patients who received 0.5 mg of Lucentis had a mean gain of 18.3 letters, compared to 7.3 letters in the placebo group
Among the data presented included results from a Phase II, 73-patient study in venous stasis ulcers showing that the all doses of Tß4 were well tolerated, with the mid-dose group showing a 33.3 percent response rate in time to healing compared to 23.5 percent in the placebo group, and Tß4 decreased the median time to healing by 45 percent among all groups
Stage I consisted of 28 days of treatment for three dose groups (125 mg, 250 mg and 500 mg orally twice daily), and a placebo group, totaling approximately 200 patients, with about 50 patients in each group
The groups treated with 100 mg of R788 bid (twice a day) and 150 mg qd (once a day) reported higher ACR 20, ACR 50, ACR 70 and DAS28 response rates than the placebo group
Pfizer Inc., of New York, said results from a randomized Phase III trial demonstrated that median progression-free survival was 11.1 months in patients with advanced pancreatic islet cell tumors treated with Sutent (sunitinib malate) compared with 5.5 months in the placebo group
In the placebo-controlled spasticity trial, 62 percent of the caregivers rated the efficacy as "good" or "very good" compared to 33 percent for the placebo group
The patient group receiving CF101 demonstrated statistically significant improvement in superficial punctate keratitis, relative to the placebo group, as measured by fluorescein staining
The median percentage decrease from baseline in pain scores was 23 percent in the KRN5500 group compared to 0 percent decrease in the placebo group (p = 0.03
The median TTAS was 91.1 hours for those receiving a single, 600-mg injection of peramivir vs. 106.1 hours observed in the placebo group...Mean reduction in trough sitting diastolic blood pressure from baseline of 10.1 mm Hg, 9.9 mm Hg, 10.7 mm Hg and 5.3 mm Hg were observed for the darusentan 50 mg, 100 mg, 300 mg and placebo groups, respectively
GTx Inc., of Memphis, Tenn., said a Phase III trial of advanced prostate cancer patients being treated with androgen deprivation therapy (ADT) showed nearly one in four placebo group subjects developed bone fractures or critical bone loss (> 7 percent loss) within two years...That analysis of placebo group data from the Phase III trial evaluating toremifene 80 mg for the prevention of bone fractures in men with prostate cancer on ADT was presented at the American Urological Association meeting in
Among the subpopulation of 78 patients who reached the 18-month study visit, the median growth rate of the lesions in the 300-mg group was 22.7 percent vs. 41.6 percent in the placebo group
A total of 120 patients will be enrolled, with 30 patients for each of the three treatment groups and placebo group